For nearly half of people diagnosed with lung cancer, immunotherapy can slow the disease but not stop it. Funded through a $4 million joint investment from the Canadian Cancer Society (CCS) and the Weston Family Foundation, a new clinical trial aims to change that.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
A new survey study SC32S, collecting sociodemographic data from clinical trial participants, has now opened across Canada. This study will help researchers understand the feasibility of using a survey to gather information about trial participants’ backgrounds and everyday lives.
Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for New Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
Investigating Precision Medicine in the Adjuvant setting: a phase III Clinical Trial in Biliary tract cancer (SAFIR IMPACT BTC)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
The next CCTG Clinical Research Associate (CRA) Lunch and Learn training session will be on Wednesday Jun 24th, 2025, at 12 pm ET, covering the top
ALC.10 (MM1OA-EA02), another myeloMATCH study, has opened in Canada comparing the usual treatment for FLT3 mutated acute myeloid leukemia (AML) with a new drug using two different treatment schedules to see if it improves outcomes for older patients.
“Older patients with FLT3 mutations, particularly FLT3-ITD, appear to benefit less from the current treatment with azacitidine and venetoclax,” says Dr. David Sanford, the ALC.10 Canadian study chair and a hematologist at BC Cancer. “ALC.10 is designed to test two different schedules of the triplet combination and if positive, the study may support a new, urgently needed treatment approach for this relatively large subset of AML patients.”
In this study the drug gilteritinib, a class of medications called kinase inhibitors, will be added to the current two drug treatment. It has different modes of action and acts as a differentiating agent for the bone marrow cells as well as helping to overcome resistance to venetoclax.
“The study will focus on elderly patients who are not always healthy enough to sustain more rigorous treatment options and will include younger, less fit patients who also may not tolerate more chemo intensive regimens,” says Dr. Lois Shepherd the ALC.10 senior investigator.
The outcome of this clinical trial may help doctors understand if these different approaches are better and if the study drugs lead to a higher percentage of senior patients achieving a deeper remission.
A Randomized Phase II Study of Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated Acute Myeloid Leukemia (AML): A myeloMATCH Treatment Trial
Final results from the CCTG HN.9 (EORTC 1740-HNCG) were presented at ASCO 2026, highlighting the challenges of reducing treatment intensity while maintaining outcomes for patients with human papillomavirus (HPV)-positive oropharyngeal cancer.
New findings presented at ASCO 2026 demonstrate that a structured exercise program for colon cancer survivors improves survival outcomes and reduces healthcare system costs.
The results of the BR.31 global Phase III study, testing adjuvant durvalumab in patients with completely resected non–small cell lung cancer (NSCLC) were published in the Journal of Clinical Oncology.
Pausing endocrine treatment to attempt pregnancy can be considered - no additional risk of recurrences after 5 years. The MAC18 (POSITIVE) study, evaluating the pregnancy outcomes and safety of interrupting endocrine therapy for young women
The Cancer Research Institute (CRI) and the Canadian Cancer Trials Group (CCTG) announced the enrollment of the first patient in the third sub study IND240C of their ongoing Immunotherapy Platform Study in Platinum-Resistant High-Grade Serous Ovarian Cancer (IPROC).
Results from the primary analysis of the ctDNA-negative cohort from the international DYNAMIC-III (CO.29) clinical trial were presented during the Presidential Symposium of the European Society for Medical Oncology Congress in Berlin
No Chemotherapy in Intermediate-risk HR + HER2- Early Breast Cancer Treated with Ribociclib (NoLEEta)
Combination Therapy with Luspatercept in Lower Risk Myelodysplasia: A Tier 1 myeloMATCH Substudy
Selective Index Node Resection vs Lymph Node Dissection after Neoadjuvant Immunotherapy for Stage IIIB-D Melanoma The Multicentre Selective Lymphadenectomy Trial-3 (MSLT-3)
NeoAdjuvant-only or Peri-operative cemiplimab in high-grade localised soft-tissue SARcoma (NAPStAR)
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial - RATIONAL-PT
Using SMART to optimize the stepped care delivery of TEMPO – a Tailored, dyadic, wEb-based physical activity and self-Management PrOgram for men with prostate cancer and their caregivers (TEMPO)
Feasibility, Acceptability and Representativeness: Collecting Sociodemographic Data in CCTG Trials
We are pleased to welcome Lesley Beaton as the new patient representative supporting the Gastrointestinal Disease Site Committee.
Lesley lives in Vancouver, BC, and brings both scientific and personal experience to her role. She spent more than three decades working in microbiology and regulatory compliance with Health Canada, gaining a scientific perspective on healthcare systems.
Please join us in welcoming Catherine Caule, who is the new patient representative supporting the Hematology Disease Site Committee.
Catherine is a long-time health advocate based in Ottawa, Ontario, and a 25-year member of the Lymphoma Support Group of Ottawa. After being diagnosed with advanced Hodgkin Lymphoma and participating in a clinical trial for relapsed disease, she became a passionate voice for patient-centered care and equitable access.
Join us in welcoming a new patient representative, Tracey Kitz who will be supporting the Hematology Committee.
Tracy Kitz is an optometrist living in Edmonton, Alberta, who dedicates herself to understanding and meeting the needs of her patients every day. In 2009, her mother was diagnosed with multiple myeloma and underwent surgery, chemotherapy, and radiation, followed by a stem cell transplant in 2014.
